STUDY ABOUT ANTI-DEMENTIA DRUG USE IN PRIMARY CARE

被引:0
|
作者
Carracedo Martinez, Eduardo [1 ]
机构
[1] SERGAS, Area Sanit Santiago de Compostela, Santiago De Compostela, A Coruna, Spain
来源
ATENCION FARMACEUTICA | 2009年 / 11卷 / 02期
关键词
MEMANTINE; CHOLINESTERASE INHIBITORS; ALZHEIMER'S; PRIMARY CARE; ALZHEIMERS-DISEASE; MEMANTINE TREATMENT; CONTROLLED-TRIAL; DEMENTIA; MODERATE; PREVALENCE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To perform a study about the use of memantine and cholinesterase inhibitors (donepezil, galantamine and rivastigmine) in primary care. Method: Cross-sectional 3-month study in five primary care units from the Santiago de Compostela (A Coruna) Healthcare Area. Results: The prevalence in the use of anti-dementia drugs is 0.36% with a 95% confidence interval (CI 95%) of 0.27% to 0.45%. No active principle is more used than the others. 96% of patients suffer from Alzheimer and 4% of Parkinson's-related dementia. 25% of these patients use memantine together with a cholinesterase inhibitor Conclusions: There is a widespread use of anti-dementia drugs even if the cognitive benefits are not yet considered as of clinical relevance. As well, the proportion of patients that use together these two anti-dementia drugs is high even if the efficacy of such association is under question.
引用
收藏
页码:124 / 126
页数:3
相关论文
共 50 条
  • [41] Observational cohort study: deprivation and access to anti-dementia drugs in the UK
    Cooper, Claudia
    Lodwick, Rebecca
    Walters, Kate
    Raine, Rosalind
    Manthorpe, Jill
    Iliffe, Steve
    Petersen, Irene
    AGE AND AGEING, 2016, 45 (01) : 148 - 154
  • [42] Is Drug Treatment for Dementia Followed Up in Primary Care? A Swedish Study of Dementia Clinics and Referring Primary Care Centres
    Sonde, Lars
    Johnell, Kristina
    PLOS ONE, 2013, 8 (02):
  • [43] A population-based study of dosing and persistence with anti-dementia medications
    Linda Brewer
    Kathleen Bennett
    Cora McGreevy
    David Williams
    European Journal of Clinical Pharmacology, 2013, 69 : 1467 - 1475
  • [44] Pharmacokinetic study of FK960, a novel anti-dementia drug, using PET in conscious monkeys.
    Noda, A
    Takamatsu, H
    Murakami, Y
    Yajima, K
    Nishimura, S
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 235P - 235P
  • [45] Evolution of Alzheimer's disease at 24 months according to the anti-dementia drug treatment
    Lopez Pousa, S.
    Turro Garriga, O.
    Calvo Perxas, L.
    Monserrat Vila, S.
    Vilalta Franch, J.
    Garre Olmo, J.
    REVISTA DE NEUROLOGIA, 2014, 59 (09) : 425 - 425
  • [46] Use of Medicines with Anticholinergic and Sedative Effect Before and After Initiation of Anti-Dementia Medications
    Gadzhanova S.
    Roughead E.
    Robinson M.
    Drugs - Real World Outcomes, 2015, 2 (1) : 53 - 60
  • [47] Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer's Disease Patients in Japan: LIFE Study
    Fukuda, Haruhisa
    Maeda, Megumi
    Murata, Fumiko
    Murata, Yutaka
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 90 (03) : 1177 - 1186
  • [48] Therapy of the Alzheimer-dementia - Modern anti-dementia recommended by experts
    Oetzel, Stefan
    NERVENHEILKUNDE, 2007, 26 (11) : 1051 - 1051
  • [49] The Gottfries-Brane-Steen Scale:: Validity, reliability and application in anti-dementia drug trials
    Bråne, G
    Gottfries, CG
    Winblad, B
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (01) : 1 - 14
  • [50] Brain concentration of a novel anti-dementia drug, FK960, in normal volunteers.
    Matsunari, I
    Murakami, Y
    Noda, A
    Yajima, K
    Takamatsu, H
    Matsudaira, M
    Nishimura, S
    Itoh, M
    Tonami, N
    Hisada, K
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 219P - 220P